Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2021-11-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于召开2021年第三次临时股东大会的通知
Regulatory Filings Classification · 95% confidence The document is a detailed notice about the convening of the 2021 third extraordinary general meeting of shareholders for Kunming Pharmaceutical Group Co., Ltd. It includes information about the meeting date, voting methods, agenda items including board and supervisory committee elections, voting instructions, and proxy forms. The content focuses on the announcement and procedural details of a shareholders' meeting rather than the meeting materials or results themselves. There is no financial data or report content, nor is it a transcript or presentation. This fits the category of a formal meeting notice or announcement for a shareholder meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is a notice of the meeting and voting procedures rather than the solicitation materials or proxy statement sent to shareholders, it is best classified as a Regulatory Filing (RNS) as a fallback for regulatory announcements that do not fit other categories. The document length is under 5,000 characters, and it is an announcement of a meeting, not the meeting materials or results. Therefore, the best classification is Regulatory Filings (RNS).
2021-11-22 Chinese
昆药集团股份有限公司监事会议事规则
Governance Information Classification · 95% confidence The document is titled as the 'Rules of Procedure for the Supervisory Board' of Kunming Pharmaceutical Group Co., Ltd., revised in November 2021. It details the structure, responsibilities, meeting procedures, rights, and duties of the supervisory board members. The content is focused on governance, internal control, supervisory roles, meeting rules, and compliance with laws and regulations. There is no financial data, earnings information, audit results, or announcements of voting or capital changes. The document is a governance-related internal rules document, not a report or announcement of financial results or corporate actions. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail support a high confidence in this classification.
2021-11-22 Chinese
昆药集团九届四十五次董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a board meeting resolution by Kunming Pharmaceutical Group Co., Ltd. It details the approval of the company's 2021 third quarter report and the decision regarding the sale of assets by a subsidiary. The document is short (823 characters) and primarily reports on board decisions rather than providing the full quarterly report or detailed financial data. It is not the quarterly report itself but an announcement of board resolutions. Therefore, it fits best under Board/Management Information (MANG).
2021-10-21 Chinese
昆药集团九届三十三次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a supervisory board resolution announcement regarding the company's 2021 third quarter report. It states that the supervisory board reviewed and approved the Q3 report, which is published on the stock exchange website. The document itself does not contain the full quarterly report or detailed financial data but rather the supervisory board's approval and opinion on the report. The document length is short (672 characters) and serves as an announcement of the supervisory board's resolution and opinion on the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a formal announcement related to regulatory compliance and supervisory board opinion, rather than the full Interim/Quarterly Report (IR).
2021-10-21 Chinese
昆药集团2021年第三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled '昆药集团2021 年第三季度报告' which translates to 'Kunming Pharmaceutical Group 2021 Third Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the third quarter of 2021. The report is unaudited as indicated. The content includes comprehensive financial figures and analysis for a period shorter than a full fiscal year (quarterly). This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or certification. Therefore, the correct classification is IR with high confidence. Q3 2021
2021-10-21 Chinese
北京德恒（昆明）律师事务所关于昆药集团股份有限公司2021年第二次临时股东大会的法律意见
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the procedures, attendance, and validity of a company's 2021 second extraordinary general meeting (临时股东大会). It discusses the convening, attendance, voting procedures, and results of the shareholders' meeting. It does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. It is a legal opinion related to a shareholders' meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the legality and validity of the meeting and voting outcomes.
2021-10-14 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.